Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.

Scott KA, Amirehsani KA.

J Am Assoc Nurse Pract. 2015 Apr;27(4):190-6. doi: 10.1002/2327-6924.12161. Epub 2014 Jul 25.

PMID:
25066647
2.

Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.

Brunetti L, Chen C, White J.

Consult Pharm. 2014 Mar;29(3):169-78. doi: 10.4140/TCP.n.2014.169. Review.

PMID:
24589766
3.

Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT.

Stroke. 2016 Feb;47(2):441-9. doi: 10.1161/STROKEAHA.115.011476. Epub 2016 Jan 5.

PMID:
26732563
4.

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

Blair HA, Keating GM.

Drugs. 2017 Mar;77(3):331-344. doi: 10.1007/s40265-017-0699-z. Review.

PMID:
28185082
5.

Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Garnock-Jones KP.

Am J Cardiovasc Drugs. 2011;11(1):57-72. doi: 10.2165/11206400-000000000-00000.

PMID:
21265583
6.

Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.

Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.

Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):126-34. doi: 10.1161/CIRCOUTCOMES.115.002369. Epub 2016 Jan 26. Review.

PMID:
26812933
7.

Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.

Waks JW, Zimetbaum PJ.

Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1461-71. doi: 10.1586/14779072.2013.849572. Epub 2013 Oct 23.

PMID:
24147516
8.

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.

Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30.

PMID:
25359164
9.

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.

Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.

J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73. doi: 10.1016/j.jacc.2013.03.020. Epub 2013 Apr 3.

10.

Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.

Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ.

Ann Intern Med. 2017 Dec 19;167(12):845-854. doi: 10.7326/M16-1157. Epub 2017 Nov 14. Erratum in: Ann Intern Med. 2018 Aug 7;169(3):204.

PMID:
29132153
11.

Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.

Paikin JS, Haroun MJ, Eikelboom JW.

Expert Rev Cardiovasc Ther. 2011 Mar;9(3):279-86. doi: 10.1586/erc.11.21.

PMID:
21438804
12.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

PMID:
23922182
13.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
14.

Dabigatran in clinical practice.

Nagarakanti R, Ellis CR.

Clin Ther. 2012 Oct;34(10):2051-60. doi: 10.1016/j.clinthera.2012.09.008. Epub 2012 Sep 29. Review.

PMID:
23031622
15.

Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.

Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Pilote L.

Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):593-9. doi: 10.1161/CIRCOUTCOMES.114.001398. Epub 2015 Oct 27.

PMID:
26508666
16.

A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.

Wang H, Zhou Y, Rong G, Lu L, Zhang J.

Blood Coagul Fibrinolysis. 2016 Jul;27(5):563-7. doi: 10.1097/MBC.0000000000000467.

PMID:
26881855
17.

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

Langkilde LK, Bergholdt Asmussen M, Overgaard M.

J Med Econ. 2012;15(4):695-703. doi: 10.3111/13696998.2012.673525. Epub 2012 Mar 22.

PMID:
22397590
18.

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial.

Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS.

Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.

PMID:
26093161
19.

Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.

Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators.

Stroke. 2013 Jul;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990. Epub 2013 Jun 6.

PMID:
23743976
20.

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S.

Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.

PMID:
23271794

Supplemental Content

Support Center